Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neurobo Pharmaceuticals Inc (NRBO)

Neurobo Pharmaceuticals Inc (NRBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,334
  • Shares Outstanding, K 8,616
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,470 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta -0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.50
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.72
  • Most Recent Earnings $-0.55 on 11/07/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.69
  • Number of Estimates 1
  • High Estimate -0.69
  • Low Estimate -0.69
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +8.26%
on 11/15/24
3.00 -21.33%
on 10/28/24
-0.42 (-15.11%)
since 10/25/24
3-Month
2.08 +13.46%
on 10/10/24
4.32 -45.37%
on 09/09/24
-1.10 (-31.79%)
since 08/27/24
52-Week
2.08 +13.46%
on 10/10/24
6.75 -65.04%
on 03/04/24
-1.02 (-30.16%)
since 11/27/23

Most Recent Stories

More News
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.9600 (-1.75%)
ULY : 0.5030 (-4.14%)
IMUX : 1.0000 (-3.85%)
NMTC : 0.7582 (+0.03%)
SNGX : 2.95 (-4.22%)
TMG.VN : 0.190 (unch)
BLGO : 0.1950 (+8.64%)
FET : 14.21 (-1.80%)
ACFN : 18.0000 (-0.55%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0800 (-15.79%)
SOTK : 4.23 (-4.73%)
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)
NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NRBO : 2.36 (+0.43%)

Business Summary

NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 2.55
2nd Resistance Point 2.49
1st Resistance Point 2.43
Last Price 2.36
1st Support Level 2.31
2nd Support Level 2.25
3rd Support Level 2.19

See More

52-Week High 6.75
Fibonacci 61.8% 4.97
Fibonacci 50% 4.41
Fibonacci 38.2% 3.86
Last Price 2.36
52-Week Low 2.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar